Tests the EAS1 device for treating lung cancer tumors

Trial details

Who runs it

Snipe Medical

Trial code

NCT06423690

Record updated

10 December 2024

Original description

A Prospective, open label, multi center, single arm, First in Human study to assess the safety and initial performance of EAS1 system for Irreversible Electroporation (IRE) ablation of lung cancer in subjects eligible for tumor resectionRead full original descriptionShow less

Snipe Medical First In Human Study

A Prospective, open label, multi center, single arm, First in Human study to assess the safety and initial performance of EAS1 system for Irreversible Electroporation (IRE) ablation of lung cancer in subjects eligible for tumor resection

Inclusion: Adult male and female subjects (age ≥18 years at the date of informed consent signature); Subject is capable and willing to provide an informed consent; Subjects with a known diagnosis of lung cancer at cT1a-T1c, cN0 stages; At least one pulmonary tumor (primary or metastasis) ≤ 30 mm in maximal diameter, as confirmed by the latest standard of care imaging (CT/MRI), performed preferably up to 30 days prior to screening; Subjects who are scheduled or deemed eligible by a thoracic surgeon for lung tumor resection; Subject is able and willing to comply with the study procedures and visits; There is ≥ 5mm of nodule-free lung parenchyma between target nodule and pleura or fissure, as confirmed by the latest standard of care imaging (CT/MRI), performed preferably up to 30 days prior to screening; ECOG 0-1; Stable doses of concomitant medications for at least four (4) weeks prior to enrollment.

Exclusion: Subjects with contraindication for tumor resection; Active and/or prolonged lung or bronchi infection, required an antibiotic treatment up to 21 days prior to screening and for more than 10 days of treatment; Previous surgery in the lung intended for ablation; thoracic major surgery at the side intended for ablation; Subjects with implanted metal or electronic thoracic devices objects (such as pacemaker) that cannot be removed prior to procedure; Participation in any other interventional clinical trial with medication, medical device and/or supplements within 30 days prior to informed consent signature; Severe emphysema, Bullous Emphysema or chronic obstructive pulmonary disease (COPD) (GOLD III/IV); Anticoagulation treatment that cannot be discontinued prior to the ablation, or a bleeding diathesis or platelets <100 )K/µl); Total Lung Capacity (TLC)< 80% of expected for age; An inability to provide informed consent; Subjects with life expectancy <12 months; Target nodule is abutting main stem bronchus, main pulmonary vasculature, esophagus and/or trachea; Subjects with Forced Expiratory Volume (FEV1) <50%; Diffusing Capacity (DCO) < 60% of expected; Oxygen saturation in free air of <88%, or requiring more than 2 l/min oxygen to achieve saturation of 92%; PCO2 of ≥ 45mm/Hg; Subjects in exacerbations group E (high risk; ≥2 exacerbations per year or ≥1 requiring hospitalization and any level of symptoms); Known history or current evidence of a significant bronchiectasis; Evidence of lung Bullae the occupies more than one third of the lung intended for ablation; Pregnant or breastfeeding female subjects or female subjects who plan pregnancy during participation in the study; Highly hypoxemic patients, according to investigator's discretion; Subjects with contraindication for bronchoscopy; Any subject who, at the discretion of the investigator, may be jeopardized by study participation.

ClinicalTrials.gov NCT06423690